[HTML] tandfonline.com

[HTML][HTML] 5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective

P Huot - Neurodegenerative Disease Management, 2018 - Taylor & Francis
Activation of 5-HT1A receptors is a potential approach to reduce L-3, 4-
dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in Parkinson's disease (PD) …
被引用次数：13 相关文章

[引用][C] 5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective.

P Huot - Neurodegenerative Disease Management, 2018 - europepmc.org
5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …

[引用][C] 5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective

P Huot - Neurodegenerative disease management, 2018 - pubmed.ncbi.nlm.nih.gov
5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective 5-HT 1A
agonists and dyskinesia in Parkinson's disease: a pharmacological perspective Neurodegener …

5-HT1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective

P Huot - Neurodegenerative Disease Management, 2018 - search.proquest.com
L-DOPA-induced dyskinesia eventually affects as many as 94% of patients with PD (1).
Because the dopaminergic system undergoes degeneration in PD, taking advantage of …